A Close Look at the Clinical Efficacy of Rho-Associated Protein Kinase Inhibitor Eye Drops for Fuchs Endothelial Corneal Dystrophy

Shigeru Kinoshita; Kathryn A Colby; Friedrich E Kruse

doi:10.1097/ICO.0000000000002642

A Close Look at the Clinical Efficacy of Rho-Associated Protein Kinase Inhibitor Eye Drops for Fuchs Endothelial Corneal Dystrophy

Cornea. 2021 Oct 1;40(10):1225-1228. doi: 10.1097/ICO.0000000000002642.

Authors

Shigeru Kinoshita¹, Kathryn A Colby², Friedrich E Kruse³

Affiliations

¹ Department of Frontier Medical Science and Technology for Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
² Department of Ophthalmology, New York University (NYU), New York, NY; and.
³ Department for Ophthalmology, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany.

Abstract

The current understanding on the clinical efficacy of Rho-associated protein kinase (ROCK) inhibitor for treating Fuchs endothelial corneal dystrophy is summarized to clarify whether the "off-label" ROCK-inhibitor eye-drop application are appropriate. ROCK-inhibitor eye drops may eventually be deemed a cutting-edge therapy for Fuchs endothelial corneal dystrophy patients with acute corneal endothelial defect.

MeSH terms

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / administration & dosage
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / analogs & derivatives
Administration, Ophthalmic
Benzoates / administration & dosage
Clinical Trials as Topic
Fuchs' Endothelial Dystrophy / drug therapy*
Humans
Isoquinolines / administration & dosage
Ophthalmic Solutions
Protein Kinase Inhibitors / administration & dosage*
Sulfonamides / administration & dosage
Treatment Outcome
beta-Alanine / administration & dosage
beta-Alanine / analogs & derivatives
rho-Associated Kinases / antagonists & inhibitors*

Substances

Benzoates
Isoquinolines
K-115
Ophthalmic Solutions
Protein Kinase Inhibitors
Sulfonamides
beta-Alanine
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
rho-Associated Kinases
fasudil
netarsudil